Thai Diabetes Devices Market, Forecast to 2023

Thai Diabetes Devices Market, Forecast to 2023

The Professional Testing Segment will See a High Growth Rate of 10% in this High-cost Device Market

RELEASE DATE
07-Feb-2020
REGION
Asia Pacific
Research Code: PAC2-01-00-00-00
SKU: HC03270-AP-MR_24137
$3,000.00
In stock
SKU
HC03270-AP-MR_24137
$3,000.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Diabetes is a growing global concern, with more than 425 million people suffering the world over. Thailand is no exception. It has a high prevalence of about 8%; there were an estimated 4.25 million diabetics in the country in 2018. Unfortunately, only about 56% of this population is actually diagnosed, meaning almost half of those diabetics are diagnosed only at later stages, often after complications arise; complications that decrease quality of life but increase the cost of care.

As the Thai population is predominantly uninsured and not covered for high-cost diabetes management devices, glucose levels tend to be irregularly monitored. This results in even the diagnosed population developing health complications from the condition. The market potential for diabetes devices in Thailand or other Asia-Pacific countries is huge but is hampered by access and affordability. For any company targeting these markets, it is crucial that it understands the current competitive landscape; reimbursement and regulatory policies; and the distribution structure, to determine its opportunity and the best go-to-market strategy.

There are four categories of medical devices that are crucial for diabetics: self-monitoring of blood glucose (SMBG) and the professional point-of-care testing (POCT); continuous glucose monitoring (CGM); insulin pens; and insulin pumps. Broadly, these devices can be classified under monitoring (SMBG, POCT, and CGM), and management (insulin pens and insulin pumps).

Most of the countries in the Asia-Pacific region import these devices. Multinational majors, and in the case of SMBG some low-cost manufacturers from China and Taiwan cater to the demand for diabetes devices. Some of the major names in the SMBG and POCT testing space are Roche, Abbott, LifeScan, and Ascensia Diabetes Care. In the case of CGM, Medtronic dominates Asia-Pacific, as global majors Dexcom and Abbott have not yet ventured into this region. The insulin pen segment is dominated by Novo Nordisk, Sanofi, and Eli Lilly, though a few other participants (for e.g., Biocon from India) may also be present, depending on the country in question. The insulin pump segment too is also dominated by Medtronic; however, the South Korean SOOIL Development is present in a few APAC countries. Medtronic supplies either a basic and/or an advanced version of its pumps, depending on the country in question. Other western players such as Insulet have not yet entered this market.

This study provides an in-depth view of each of the 4 segments: SMBG and POCT; CGM; insulin pens; and insulin pumps through the analyses of drivers, restraints, revenue forecasts, average selling prices of products and consumables, the market shares of top participants, their market strategies, and route to market. In addition, it provides a country-level overview of public health policies for diabetics, reimbursement and regulatory insights, and offers distribution insights by highlighting key distributors and growth opportunities in the country.

Author: Siddharth Shah

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Key Findings (continued)

Diabetes Prevalence and Diagnosis Trends

Diabetes Devices Market Participants

Diabetes Devices Market Participants (continued)

Thailand Glucose Monitoring and Diabetes Management

Distribution Insights—Thailand

Market Definitions

Scope and Segmentation

Revenue Forecast by Device Type

Revenue Forecast Discussion

Market Drivers

Market Restraints

Revenue Forecast by Device Type

Revenue Forecast Discussion

Revenue Forecast by Application

Revenue Forecast Discussion

Personal SMBG Devices Market Share

Professional SMBG Devices Market Share

SMBG Devices Market Participant Strategy

POCT Devices Market Participant Strategy

SMBG Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast by Device Type

Revenue Forecast Discussion

Market Share

Market Participant Strategy

Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast

Insulin Pen Market Revenue Forecast Discussion

Market Share

Market Participant Strategy

Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast

Revenue Forecast Discussion

Insulin Pump Market Share

Market Participant Strategy

Route-to-Market Analysis

Country Policies for Diabetes

Diabetes Device Regulatory Insights

Reimbursement and Insurance Insights

Route to Market

Key Distributors

Growth Opportunity 1—Unlocking Untapped Potential

Growth Opportunity 2—Professional Testing

Strategic Imperatives for Success and Growth

Legal Disclaimer

3 Big Predictions

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
Diabetes is a growing global concern, with more than 425 million people suffering the world over. Thailand is no exception. It has a high prevalence of about 8%; there were an estimated 4.25 million diabetics in the country in 2018. Unfortunately, only about 56% of this population is actually diagnosed, meaning almost half of those diabetics are diagnosed only at later stages, often after complications arise; complications that decrease quality of life but increase the cost of care. As the Thai population is predominantly uninsured and not covered for high-cost diabetes management devices, glucose levels tend to be irregularly monitored. This results in even the diagnosed population developing health complications from the condition. The market potential for diabetes devices in Thailand or other Asia-Pacific countries is huge but is hampered by access and affordability. For any company targeting these markets, it is crucial that it understands the current competitive landscape; reimbursement and regulatory policies; and the distribution structure, to determine its opportunity and the best go-to-market strategy. There are four categories of medical devices that are crucial for diabetics: self-monitoring of blood glucose (SMBG) and the professional point-of-care testing (POCT); continuous glucose monitoring (CGM); insulin pens; and insulin pumps. Broadly, these devices can be classified under monitoring (SMBG, POCT, and CGM), and management (insulin pens and insulin pumps). Most of the countries in the Asia-Pacific region import these devices. Multinational majors, and in the case of SMBG some low-cost manufacturers from China and Taiwan cater to the demand for diabetes devices. Some of the major names in the SMBG and POCT testing space are Roche, Abbott, LifeScan, and Ascensia Diabetes Care. In the case of CGM, Medtronic dominates Asia-Pacific, as global majors Dexcom and Abbott have not yet ventured into this region. The insulin pen segment is dominated by Novo Nordisk, Sanofi, and Eli Lilly, though a few other participants (for e.g., Biocon from India) may also be present, depending on the country in question. The insulin pump segment too is also dominated by Medtronic; however, the South Korean SOOIL Development is present in a few APAC countries. Medtronic supplies either a basic and/or an advanced version of its pumps, depending on the country in question. Other western players such as Insulet have not yet entered this market. This study provides an in-depth view of each of the 4 segments: SMBG and POCT; CGM; insulin pens; and insulin pumps through the analyses of drivers, restraints, revenue forecasts, average selling prices of products and consumables, the market shares of top participants, their market strategies, and route to market. In addition, it provides a country-level overview of public health policies for diabetics, reimbursement and regulatory insights, and offers distribution insights by highlighting key distributors and growth opportunities in the country. Author: Siddharth Shah
More Information
No Index No
Podcast No
Author Siddharth Shah
Industries Healthcare
WIP Number PAC2-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9A49-B1,9A4B-B1